Actively Recruiting

Phase 3
Age: 29Weeks - 36Weeks
All Genders
NCT05960929

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

Led by ONY · Updated on 2025-03-30

220

Participants Needed

10

Research Sites

65 weeks

Total Duration

On this page

Sponsors

O

ONY

Lead Sponsor

A

Avania

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this clinical study is to determine the effectiveness and safety of Infasurf® administered through the InfasurfAero™, a novel oral airway delivery device specifically designed to give Infasurf in a less complicated way and without the need for a breathing tube or interrupting nasal respiratory support.

CONDITIONS

Official Title

InfasurfAero™ Versus Sham Treatment in Preterm Newborns With RDS

Who Can Participate

Age: 29Weeks - 36Weeks
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Written informed consent obtained by parent or legal representative prior to or after birth
  • Gestational age at birth 29 29 0/7 and 29 35 6/7 weeks
  • Birthweight 29 1,000 and 29 3,500 grams
  • Age 29 1 hour and 29 6 hours
  • Clinical diagnosis of surfactant-deficient RDS with either Silverman-Anderson Retraction Score 29 5 in room air or signs of respiratory distress plus radiographic confirmation
  • Require continuous positive airway pressure (CPAP)
  • Respiratory Severity Score (RSS) 29 1.25 and 29 2.4
  • If gestational age is greater than 34 6/7 weeks, a chest radiograph is required
Not Eligible

You will not qualify if you...

  • Surfactant administration prior to randomization
  • Mechanical ventilation prior to randomization
  • Major congenital anomaly (suspected or confirmed)
  • Abnormality of the airway (suspected or confirmed)
  • Respiratory distress due to causes other than RDS (e.g., pulmonary hypoplasia, pneumothorax, meconium aspiration syndrome, pneumonia, septic or hypovolemic shock, hypoxic ischemic encephalopathy)
  • Apgar score less than 3 at 5 minutes of age
  • Umbilical cord gas pH less than 7.0 or base deficit greater than 10
  • Any condition that places the neonate at undue risk according to the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

St. Josephs Hospital and Medical Center

Phoenix, Arizona, United States, 85013

Actively Recruiting

2

Phoenix Children's

Phoenix, Arizona, United States, 85016

Actively Recruiting

3

Sharp Mary Birch Hospital for Women & Newborns

San Diego, California, United States, 92123

Actively Recruiting

4

University of Florida -Jacksonville

Jacksonville, Florida, United States, 32209

Actively Recruiting

5

Kapi'olani Medical Center for Women & Children

Honolulu, Hawaii, United States, 96826

Actively Recruiting

6

Jersey Shore University Medical Center

Neptune City, New Jersey, United States, 07753

Actively Recruiting

7

Sisters of Charity Hospital

Buffalo, New York, United States, 14214

Actively Recruiting

8

Western TN- Jackson-Madison County General Hospital

Jackson, Tennessee, United States, 38301

Actively Recruiting

9

Utah Valley Hospital

Provo, Utah, United States, 84604

Actively Recruiting

10

Unity Point Meriter

Madison, Wisconsin, United States, 53715

Actively Recruiting

Loading map...

Research Team

C

Corey Commaroto, RRT

CONTACT

D

Dan Swartz, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here